PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
27
04
2018
revised:
23
07
2018
accepted:
15
11
2018
pubmed:
22
11
2018
medline:
5
3
2020
entrez:
22
11
2018
Statut:
ppublish
Résumé
Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression in tumors seems to be a prerequisite for treatment response. However, PD-L1 is heterogeneously expressed within tumor lesions and may change upon disease progression and treatment. Imaging of PD-L1 could aid in patient selection. Previously, we showed the feasibility to image PD-L1
Identifiants
pubmed: 30459153
pii: 2326-6066.CIR-18-0280
doi: 10.1158/2326-6066.CIR-18-0280
doi:
Substances chimiques
Antibodies, Monoclonal
0
B7-H1 Antigen
0
Indium Radioisotopes
0
Indium-111
E9NGC49E0T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-161Informations de copyright
©2018 American Association for Cancer Research.